drug
LIRAGLUTIDE
Preclinicalupdated 3mo agoby $LEXX Lexaria Bioscience Corp.
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval110 co-mentions · 55 sources
- drugVICTOZA104 co-mentions · 56 sources
- drugSaxenda75 co-mentions · 56 sources
- companyNovo Nordisk Inc30 co-mentions · 30 sources
- companyBiocon Pharma Ltd2 co-mentions · 2 sources
- companyFresenius Kabi USA LLC1 co-mentions · 1 sources
- tagDrug Shortage1 co-mentions · 1 sources
- drugRNS-601 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying LIRAGLUTIDE
- phase1Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
- —Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
- phase4A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- —Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
- —Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- phase3SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
- phase4Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
- N/AThe Evira Study: Additional Support During Anti-Obesity Treatment
News(4)
- Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructureThe additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…biospace · 10d ago
- Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearoutPfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.fiercebiotech · 10d ago
- Compounders maintain a firm grip on the GLP-1 marketDespite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.biopharma_dive · 28d ago
- STAT+: FDA wants to exclude weight loss drugs from a compounding listFDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.stat · 3mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that